Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Zealand Pharma and Fluoguide posted very positive phase II results paving the way for further studies, and CS Medica signed a contract regarding their pain patch for the Spanish and Portugese markets. Many companies experienced declining share prices without posting any news.
Only 4 of the 20 listed, Danish biotech companies published news the past week. 3 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Saniona is still the best performing stock this year.
Company news the past week
Ascendis Pharma
No news the past week
No news the past week
Cessatech
No news the past week
CS MEDICA A/S Signs New Own-Label Agreement on Pain Patch (Link)
No news the past week
Evaxion Biotech
No news the past week
Expres2ion
No news the past week
Fluoguide
FluoGuide announces positive interim results from phase IIa trial of FG001 in head & neck cancer (Link)
Genmab
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’ (Link)
Gubra
No news the past week
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906) (Link)
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions (Link)
Y-mAbs Therapeutics
No news the past week
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a negative share price performance last week of -5.6%. In the past week, Fluoguide became the best performing stock with an 5% increase after a positive phase IIa trial of FG001 in head & neck cancer. Data showed all 12 patients had their tumors lit up with FG001. Cessatech and Expres2ion were the only Danish biotech stocks that also delivered a positive return in the past week. On the other end of the spectre, Saniona AB became the worst performing stock with a 22% decrease without posting any news. However, it may be due to the fact that the share has already taken off in 2023 with a 178% increase. Curasight A/S, Zealand Pharma A/S and Saniona AB continue to be the best performing stocks year-to-date after soaring 136-178% after among other things partnerships and positive recommendations from authorities paving the way for approvals. The Danish biotech stocks have done great year-to-date with a total return of 8.2%.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
